Merck Serono Ventures, Compugen Team Up On Drug Toxicity Biomarker Start-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Partnership is first investment under Merck Serono Ventures’ €10 million Israel Bioincubator Program.